TACE + RFA COMBINATION
FOR INTERMEDIATE HCC: THE CHINESE STANDARD
For HCC between 3 and 7 cm — too large for reliable single-treatment RFA, too high-risk for surgery in many cirrhotic patients — sequential TACE followed by RFA has become the dominant approach at Chinese academic centres, supported by randomised trial evidence showing survival benefit over TACE alone.
analyticsAt a Glance
- check_circleTACE first: reduces arterial blood flow (eliminating heat sink), marks tumour with lipiodol, causes partial necrosis
- check_circleRFA 2–6 weeks later: ablates lipiodol-stained tumour with better targeting and reduced heat sink effect
- check_circleRCT evidence: combination significantly outperforms TACE alone for HCC 3–7 cm
- check_circleChinese academic centres perform 500–1,000+ TACE+RFA courses annually — world's most experienced
Why the Combination Works: The Complementary Logic
TACE and RFA have complementary mechanisms — each addresses the other's limitations. Understanding why the combination outperforms either treatment alone requires understanding what each cannot do.
“TACE is good at cutting off blood supply but not at creating cell death at margins. RFA is good at creating a precise zone of necrosis but is hampered by blood flow. Together, TACE removes the blood flow that hampers RFA, and RFA delivers the precise local destruction that TACE cannot achieve.”
What TACE Does (and Cannot Do)
TACE (transarterial chemoembolisation) injects chemotherapy-soaked lipiodol emulsion and embolic particles into the tumour's feeding artery — cutting off blood supply and delivering local chemotherapy. For HCC 3–7 cm, TACE achieves complete pathological necrosis in only 20–40% of tumours. It reliably causes partial necrosis, lipiodol retention in the tumour, and reduction in blood flow — but rarely achieves the complete destruction that ablation can provide.
What TACE Fixes for RFA
TACE's arterial embolisation dramatically reduces blood flow through the tumour and surrounding vessels — directly addressing the heat sink effect that limits RFA for perivascular tumours. Less blood flow means less heat dissipation during RFA energy delivery, enabling higher sustained temperatures throughout the tumour. The lipiodol retained in the tumour after TACE also acts as a CT marker — making the tumour easier to target precisely on CT-guided RFA even when visibility was previously poor.
Evidence: TACE + RFA vs TACE Alone
Key outcomes from published RCTs and meta-analyses comparing TACE + RFA to TACE monotherapy for intermediate HCC.
Survival Outcomes — TACE+RFA vs TACE Alone (HCC 3–7 cm)
Pooled survival data from published Chinese RCTs. All showed significantly improved OS and PFS with combination vs TACE alone for HCC 3–7 cm.
- 3-Year OS — TACE + RFA50–65%
- 3-Year OS — TACE Alone30–45%
- 5-Year OS — TACE + RFA32–48%
- 5-Year OS — TACE Alone15–27%
Complete Necrosis and Local Recurrence
Local efficacy outcomes showing TACE+RFA advantage over TACE alone in achieving complete tumour necrosis.
- Complete Necrosis — TACE + RFA (3–5 cm)75–90%
- Complete Necrosis — TACE Alone (3–5 cm)25–45%
- 2-Year Local Recurrence — TACE + RFA15–25%
- 2-Year Local Recurrence — TACE Alone45–65%
The TACE + RFA Sequential Protocol
How the combination is delivered in practice at Chinese academic centres.
- 1
Step 1: MDT Staging and TACE+RFA Planning
Contrast-enhanced CT or MRI confirms HCC characteristics (size, vascular anatomy, arterial supply). AFP, liver function (Child-Pugh score, MELD). Digital subtraction angiography (DSA) pre-planned for TACE. RFA approach mapped — electrode entry, path, number of positions.
- 2
Step 2: TACE Procedure
Femoral artery puncture under local anaesthesia. Selective catheterisation of the hepatic artery feeding the tumour under DSA guidance. Emulsion of lipiodol + cisplatin/doxorubicin/mitomycin C injected, followed by embolic material (gelatin sponge or microspheres). Lipiodol deposits in the tumour's feeding vessels, marking the entire tumour extent.
- 3
Step 3: Recovery and Imaging (2–6 Weeks)
Post-TACE syndrome (fever, nausea, right upper quadrant pain) managed for 3–5 days. CT scan at 2–4 weeks confirms lipiodol retention, assesses degree of necrosis, and confirms tumour extent for RFA planning. Window of 2–6 weeks after TACE is the optimal RFA timing — blood flow reduced, lipiodol deposited, patient recovered.
- 4
Step 4: CT-Guided RFA
Under CT guidance, the electrode is placed through the lipiodol-stained tumour. The lipiodol appears bright on unenhanced CT — dramatically improving targeting accuracy even for tumours previously difficult to see on CT. Multiple electrode positions cover the entire tumour. The reduced blood flow from TACE embolisation allows higher, more sustained temperatures during ablation — overcoming the heat sink effect.
- 5
Step 5: Response Assessment (4–6 Weeks Post-RFA)
Contrast-enhanced CT or MRI evaluates complete ablation. Complete response: no enhancement in treated area. Residual enhancement indicates incomplete ablation — prompting repeat RFA or further TACE. Complete ablation rates of 75–90% for HCC 3–5 cm with this protocol at experienced centres.
Patient Selection for TACE + RFA Combination
Who benefits most from the combination, and where other approaches are preferred.
| Factor | TACE + RFA Combination | Other Approaches |
|---|---|---|
| HCC Size | 3–7 cm (single) — core indication; optimal for combination | <3 cm: RFA alone sufficient. >7 cm: systemic therapy or transplant evaluation |
| Tumour Location | Any location — TACE + RFA reduces heat sink even for perivascular tumours | Subcapsular HCC near bowel: RFA carries perforation risk even post-TACE; discuss |
| Liver Function | Child-Pugh A (best). Child-Pugh B7: acceptable with careful selection | Child-Pugh B8–9: TACE embolisation reduces liver function further; systemic preferred |
| Number of Tumours | Single tumour 3–7 cm (primary). 2–3 tumours each 3–5 cm with adequate liver function | >3 tumours or bilobar large-volume disease: sorafenib/lenvatinib + TACE systemic approach |
| BCLC Stage | BCLC A-B overlap (large single tumour) — where combination offers curative intent | Clear BCLC B (multiple large): TACE alone per Western guidelines; China uses combination more liberally |
| Prior TACE | No prior or limited prior TACE — good arterial supply for effective embolisation | Post-multiple TACE with de-arterialisation: RFA alone may be more practical |
Explore the RFA Knowledge Base
Related RFA topics and resources.
Frequently Asked Questions
Common questions about TACE + RFA combination for HCC.
About the Combination
Why is TACE done before RFA rather than the other way around?
TACE must precede RFA to achieve the synergistic benefits. TACE embolises the tumour's arterial supply, which is what eliminates the heat sink effect and enables effective RFA. If RFA were done first, the arterial blood flow would still be present and would dissipate heat, with no benefit from the TACE that follows. The sequential order TACE → RFA (with 2–6 weeks between procedures) is integral to the combination's mechanism.
Is TACE + RFA the same as what's sometimes called cTACE + RFA?
Yes. "cTACE" (conventional TACE using lipiodol + chemotherapy + gelatin sponge embolisation) is the most common TACE variant used in the combination with RFA at Chinese academic centres. DEB-TACE (drug-eluting bead TACE) can also be combined with RFA, but the lipiodol deposition from cTACE has the added advantage of marking the tumour for improved CT-guided RFA targeting — which DEB-TACE does not provide. Most published Chinese TACE + RFA evidence uses cTACE.
Access
Is TACE + RFA available in India and other Asian countries outside China?
Yes. TACE is performed at most hepatobiliary centres globally. RFA post-TACE is available at experienced interventional oncology centres in India (Tata Memorial, Apollo, Fortis), South Korea, Japan, and Singapore. However, the volume and accumulated experience for this specific combination is highest at Chinese academic centres. For 3–7 cm HCC requiring the combination approach, CancerFax can identify both Chinese and Indian centres with appropriate TACE + RFA programme expertise.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
HCC Between 3–7 cm? TACE + RFA May Be Your Best Option.
Upload your liver CT/MRI, AFP, liver function tests, and any prior treatment records. Our hepatobiliary team will assess whether TACE + RFA combination is appropriate and identify experienced centres.
For informational purposes only. HCC combination treatment decisions require multi-disciplinary hepatobiliary team evaluation.